Masimo Ahead, But Philips Fights On In Long-Running Patent Battle
This article was originally published in The Gray Sheet
A U.S. district court upheld an Oct. 2014 ruling finding Philips guilty of infringing two Masimo patents related to pulse oximetry technology, and awarded $467 million in damages, but Philips is appealing.
You may also be interested in...
Philips and Masimo have put to rest their long legal wrangling over patient-monitoring technology patents and shaken hands on a multi-year, global sales, and marketing partnership.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.